LianBio (LIAN) Competitors $0.20 +0.01 (+3.20%) As of 04/2/2025 Add Compare Share Share Competitors Stock AnalysisChartCompetitorsDividendFinancialsInsider TradesSEC FilingsTrendsBuy This Stock LIAN vs. RANI, VTGN, HLVX, ADAG, EXOZ, ANL, AVTX, JSPR, CLSD, and PYRGFShould you be buying LianBio stock or one of its competitors? The main competitors of LianBio include Rani Therapeutics (RANI), Vistagen Therapeutics (VTGN), HilleVax (HLVX), Adagene (ADAG), Exozymes (EXOZ), Adlai Nortye (ANL), Avalo Therapeutics (AVTX), Jasper Therapeutics (JSPR), Clearside Biomedical (CLSD), and PyroGenesis Canada (PYRGF). These companies are all part of the "pharmaceutical products" industry. LianBio vs. Rani Therapeutics Vistagen Therapeutics HilleVax Adagene Exozymes Adlai Nortye Avalo Therapeutics Jasper Therapeutics Clearside Biomedical PyroGenesis Canada Rani Therapeutics (NASDAQ:RANI) and LianBio (NASDAQ:LIAN) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, earnings, institutional ownership, media sentiment, profitability, dividends, risk, analyst recommendations and community ranking. Do insiders and institutionals have more ownership in RANI or LIAN? 30.2% of Rani Therapeutics shares are owned by institutional investors. Comparatively, 74.8% of LianBio shares are owned by institutional investors. 53.3% of Rani Therapeutics shares are owned by company insiders. Comparatively, 7.6% of LianBio shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth. Do analysts rate RANI or LIAN? Rani Therapeutics currently has a consensus target price of $12.33, suggesting a potential upside of 886.67%. Given Rani Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Rani Therapeutics is more favorable than LianBio.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Rani Therapeutics 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 3.17LianBio 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Does the MarketBeat Community believe in RANI or LIAN? Rani Therapeutics received 30 more outperform votes than LianBio when rated by MarketBeat users. Likewise, 82.93% of users gave Rani Therapeutics an outperform vote while only 36.36% of users gave LianBio an outperform vote. CompanyUnderperformOutperformRani TherapeuticsOutperform Votes3482.93% Underperform Votes717.07%LianBioOutperform Votes436.36% Underperform Votes763.64% Which has preferable earnings and valuation, RANI or LIAN? Rani Therapeutics is trading at a lower price-to-earnings ratio than LianBio, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioRani TherapeuticsN/AN/A-$33.97M-$1.06-1.18LianBioN/AN/A-$110.29M-$0.81-0.25 Is RANI or LIAN more profitable? LianBio's return on equity of -33.17% beat Rani Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Rani TherapeuticsN/A -219.64% -56.71% LianBio N/A -33.17%-30.19% Does the media favor RANI or LIAN? In the previous week, Rani Therapeutics had 17 more articles in the media than LianBio. MarketBeat recorded 17 mentions for Rani Therapeutics and 0 mentions for LianBio. Rani Therapeutics' average media sentiment score of 0.27 beat LianBio's score of 0.00 indicating that Rani Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Rani Therapeutics Neutral LianBio Neutral Which has more risk & volatility, RANI or LIAN? Rani Therapeutics has a beta of 0.14, suggesting that its stock price is 86% less volatile than the S&P 500. Comparatively, LianBio has a beta of 0.23, suggesting that its stock price is 77% less volatile than the S&P 500. SummaryRani Therapeutics beats LianBio on 10 of the 16 factors compared between the two stocks. Remove Ads Get LianBio News Delivered to You Automatically Sign up to receive the latest news and ratings for LIAN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart LIAN vs. The Competition Export to ExcelMetricLianBioBiotechnology IndustryMedical SectorNASDAQ ExchangeMarket Cap$21.59M$115.21M$5.33B$7.16BDividend YieldN/A3.69%4.87%4.06%P/E Ratio-0.253.1722.9417.50Price / SalesN/A3,909.19357.9385.03Price / CashN/A13.0138.1634.64Price / Book0.0733.156.263.82Net Income-$110.29M-$87.82M$3.21B$247.19M7 Day Performance5.21%-4.36%-7.86%-7.19%1 Month Performance3.31%57.63%-2.83%-9.97%1 Year Performance-36.85%80.50%3.74%-7.26% LianBio Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)LIANLianBioN/A$0.20+3.2%N/A-37.4%$21.59MN/A-0.25110Gap UpRANIRani Therapeutics2.6484 of 5 stars$1.47-5.2%$12.33+739.0%-60.7%$84.22MN/A-1.39110Earnings ReportAnalyst ForecastAnalyst RevisionNews CoverageGap DownVTGNVistagen Therapeutics1.0655 of 5 stars$2.91+4.3%N/A-57.6%$83.99M$698,000.00-1.9740HLVXHilleVax2.4421 of 5 stars$1.68flat$3.00+78.6%-90.2%$83.67MN/A-0.5420Earnings ReportAnalyst RevisionNews CoverageADAGAdagene1.8984 of 5 stars$1.77+5.0%$8.00+352.0%-43.7%$83.39M$815,746.000.00260Analyst ForecastHigh Trading VolumeEXOZExozymesN/A$13.11-11.5%N/AN/A$81.96MN/A0.0029ANLAdlai Nortye2.4258 of 5 stars$2.30+4.1%$9.00+291.3%-78.3%$81.55M$5M0.00127Positive NewsAVTXAvalo Therapeutics2.9925 of 5 stars$7.63-0.4%$35.33+363.1%-59.6%$79.31M$820,000.000.0040JSPRJasper Therapeutics2.7298 of 5 stars$5.24+0.6%$62.50+1,092.7%-85.2%$78.72MN/A-1.1120Positive NewsCLSDClearside Biomedical2.2403 of 5 stars$1.03+2.5%$5.75+458.3%-37.1%$78.12M$7.70M-2.2930Analyst RevisionGap DownPYRGFPyroGenesis CanadaN/A$0.40+2.5%N/A+11.5%$75.59M$9.14M-6.7590High Trading Volume Remove Ads Related Companies and Tools Related Companies RANI Alternatives VTGN Alternatives HLVX Alternatives ADAG Alternatives EXOZ Alternatives ANL Alternatives AVTX Alternatives JSPR Alternatives CLSD Alternatives PYRGF Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:LIAN) was last updated on 4/4/2025 by MarketBeat.com Staff From Our PartnersTrump Allies Confirm Exec Order 14024 Triggers Dollar CollapseExecutive Order 14024 is paving the way for irreversible damage to the dollar's value—threatening your wealth,...Priority Gold | SponsoredYour Retirement Is Caught in the CrossfireWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredCaught on Camera: Elon Musk’s “Area 51”You won’t believe what tech legend Jeff Brown found in what he calls Elon Musk’s “Area 51.” (Click here to see...Brownstone Research | SponsoredRUTHLESS Musk Move >> coming June 1?Elon Musk has made headlines with everything from mass layoffs to political drama — but his next move could sh...Paradigm Press | SponsoredNearly $3 Trillion Gone…Nearly $3 trillion disappeared from the stock market on Thursday morning. According to Whitney Tilson - a f...Stansberry Research | SponsoredHow you could profit from Elon’s latest AI breakthroughEvery single one of Elon's projects minted an entire new class of millionaires. And xAI could be next in li...Behind the Markets | Sponsored🥾⛏️👷♂️ What I Learned From Numerous Mine Visits...Twenty years ago, I made a decision that changed my life. Instead of sitting behind a desk analyzing mining...Golden Portfolio | SponsoredTrump’s betrayal exposed Fair warning: this will not make for easy viewing. Especially if you voted for Trump, put your faith in hi...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding LianBio Please log in to your account or sign up in order to add this asset to your watchlist. Share LianBio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
